Evidence map›Paper›PMID 24332849›Full record

ArticleCell reports2013

USP10 antagonizes c-Myc transcriptional activation through SIRT6 stabilization to suppress tumor formation.

Zhenghong Lin, Heeyoung Yang, Can Tan, Jinping Li, Zhaojian Liu, Qiu Quan, Sinyi Kong, Junsheng Ye, Beixue Gao, Deyu Fang

Open access · goldAbstract read
In one paragraph

Article in Cell reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 131 papers.

0numbers the graph read from it
0cells of the map it votes in
131citing papers in PubMed
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

131 citing papers in PubMed, 205 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. USP10-mediated deubiquitination and activation ofActa pharmaceutica Sinica. B · 2026
    Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

71 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Zhenghong LinDepartment of Pathology, Northwestern University Feinberg School of Medicine, 303 East Chicago Avenue, Chicago, IL 60611, USA.
Heeyoung YangDepartment of Pathology, Northwestern University Feinberg School of Medicine, 303 East Chicago Avenue, Chicago, IL 60611, USA.
Can TanDepartment of Pathology, Northwestern University Feinberg School of Medicine, 303 East Chicago Avenue, Chicago, IL 60611, USA.
Jinping LiDepartment of Pathology, Northwestern University Feinberg School of Medicine, 303 East Chicago Avenue, Chicago, IL 60611, USA.
Zhaojian LiuDepartment of Pathology, Northwestern University Feinberg School of Medicine, 303 East Chicago Avenue, Chicago, IL 60611, USA.
Qiu QuanDepartment of Pathology, Northwestern University Feinberg School of Medicine, 303 East Chicago Avenue, Chicago, IL 60611, USA.
Sinyi KongDepartment of Pathology, Northwestern University Feinberg School of Medicine, 303 East Chicago Avenue, Chicago, IL 60611, USA.
Junsheng YeDepartment of Pathology, Northwestern University Feinberg School of Medicine, 303 East Chicago Avenue, Chicago, IL 60611, USA.
Beixue GaoDepartment of Pathology, Northwestern University Feinberg School of Medicine, 303 East Chicago Avenue, Chicago, IL 60611, USA.
Deyu FangDepartment of Pathology, Northwestern University Feinberg School of Medicine, 303 East Chicago Avenue, Chicago, IL 60611, USA. Electronic address: fangd@northwestern.edu.
Northwestern University · US

Funding

The roles of Sirt1, a deacetylase, in immune tolerance and autoimmunityR01AI079056 · NIAID · UNIVERSITY OF MISSOURI-COLUMBIA · PI FANG, DEYU · 2008 to 2017
$3.3M
A novel target for type 1 diabetesDP2DK083050 · NIDDK · UNIVERSITY OF MISSOURI-COLUMBIA · PI FANG, DEYU · 2008 to 2010
$2.4M
The roles of Sirt1, a deacetylase, in immune tolerance and autoimmunityR56AI079056 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI FANG, DEYU · 2012 to 2012
$386k
NIAID NIH HHS R01 AI079056NIAID NIH HHS R01AI079056NIAID NIH HHS R56 AI079056NIAID NIH HHS R56AI079056NIDDK NIH HHS DP2 DK083050NIDDK NIH HHS DP2DK083050
6 · The paper itself

Abstract

The reduced protein expression of SIRT6 tumor suppressor is involved in tumorigenesis. The molecular mechanisms underlying SIRT6 protein downregulation in human cancers remain unknown. Using a proteomic approach, we have identified the ubiquitin-specific peptidase USP10, another tumor suppressor, as one of the SIRT6-interacting proteins. USP10 suppresses SIRT6 ubiquitination to protect SIRT6 from proteasomal degradation. USP10 antagonizes the transcriptional activity of the c-Myc oncogene through SIRT6, as well as p53, to inhibit cell-cycle progression, cancer cell growth, and tumor formation. To support this conclusion, we detected significant reductions in both USP10 and SIRT6 protein expression in human colon cancers. Our study discovered crosstalk between two tumor-suppressive genes in regulating cell-cycle progression and proliferation and showed that dysregulated USP10 function promotes tumorigenesis through SIRT6 degradation.

Indexed as

Gene Expression Regulation, NeoplasticAnimalsCarcinogenesisCell Line, TumorColonic NeoplasmsHumansMiceMice, NudeNeoplasms, ExperimentalProtein StabilityProteolysisProto-Oncogene Proteins c-mycSirtuinsTranscriptional ActivationTumor Suppressor Protein p53UbiquitinationProto-Oncogene Proteins c-mycSIRT6 protein, humanSirtuinsTumor Suppressor Protein p53Ubiquitin ThiolesteraseUSP10 protein, human

Identifiers

PMID24332849
PMCPMC4007576
OpenAlexW2007072354

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.